Published in Gene Therapy Weekly, February 3rd, 2005
According to recent research published in the journal Molecular Cancer Therapeutics, "deregulated expression of the Wilms tumor gene (WT1) has been implicated in the maintenance of a malignant phenotype in leukemias and a wide range of solid tumors through interference with normal signaling in differentiation and apoptotic pathways."
"Expression of high levels of WT1 is associated with poor prognosis in leukemias and breast cancer. Using real-time (Taqman) reverse transcription-polymerase chain reaction (PCR) and RNase protection assay, we have shown up-regulation of WT1...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.